Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
A two-analyte integrated population pharmacokinetic (PK) model that simultaneously describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE following repeated administrations of polatuzumab vedotin (pola) was developed based on data from four clinical studies of pola in patients with non-Hodgkin lymphoma. A two-compartment model with a non-specific time-dependent linear clearance, a linear time-dependent exponentially declining clearance, and a Michaelis-Menten (MM) clearance provided a good fit of the acMMAE plasma PK profiles. All three acMMAE elimination pathways contributed to the input to the central compartment of unconjugated MMAE, which was also described by a two-compartmental model. Population PK parameters, covariate effects, and inter-individual variability of model parameters were estimated. The impact of clinically relevant covariates on PK exposures of each analyte were quantified and reported to support key label claims.